Kusajili – Centralise les essais cliniques mondiaux

Résultat de votre recherche par promoteur : Beaufour Ipsen Pharma S.A.S

Femme et Homme Max 99 ans
Beaufour Ipsen Pharma S.A.S MAJ Il y a 4 ans

A phase II, multicentre, multinational, prospective, randomised, double-blind, placebo controlled study assessing the efficacy and safety of a single application of three doses of Dysport in patients with upper back myofascial pain syndrome (MPS) To compare the efficacy of a single application of Dysport (100, 300 or 500 units) injected into 3 to 6 trigger points (TPs) located in the upper back musculature of adults with (MPS) with placebo

Pays Aucun
Organes Aucun
Spécialités Aucune

Essai clos aux inclusions

Plus d'informations